aibioRockwell Medical holders approve reverse stock split amendment
Tickers RMTI
Holders cast 16,993,038 votes for the reverse split and 6,597,036 against it at the June 12, 2026 annual meeting. The 8-K reports the result but gives no split ratio and no effective date.
Key facts
- Company
- Rockwell Medical, Inc. (NASDAQ: RMTI)
- News type
- Listings
- Primary source
- Rockwell Medical, Inc. 8-K (2026-06-15)
Rockwell Medical, Inc. (Nasdaq: RMTI) reported in a Form 8-K filed June 15, 2026 that its stockholders approved an amendment to the certificate of incorporation that would effect a reverse stock split of its common stock. The vote was held at the 2026 Annual Meeting of Stockholders on June 12, 2026. The 8-K is signed by Chief Executive Officer Mark Strobeck.
The split amendment received 16,993,038 votes for, 6,597,036 against and 223,632 abstentions. The 8-K does not give the split ratio, the timing of the split or the price at which the company will trade afterward.
The other proposals
Stockholders elected two Class II directors, Joseph Dawson and Joan Lau, Ph.D., to three-year terms expiring at the 2029 annual meeting. Dawson received 9,812,114 votes for, 869,022 against and 330,731 abstentions. Lau received 9,890,379 votes for, 729,615 against and 391,873 abstentions. Each election drew 12,801,839 broker non-votes.
In a non-binding advisory vote, holders approved the pay of the named executive officers with 8,232,918 votes for, 2,682,354 against and 96,595 abstentions. The same 12,801,839 broker non-votes were recorded on that item.
Holders also ratified EisnerAmper LLP as the independent registered public accounting firm for 2026, with 22,996,530 votes for, 698,744 against and 118,432 abstentions. The auditor vote shows no broker non-votes.
The money behind the company
The 10-K filed March 26, 2026 reports a net loss of $5.3 million for 2025, compared with a net loss of $480,000 for 2024. Rockwell used $659,000 in operations in 2025, after providing $4.2 million from operations in 2024. Research and development expense was $0 in 2025 and $19,000 in 2024.
Short-term investments were $14.3 million at the end of 2025, up from $5.9 million a year earlier. Cash and cash equivalents were $15.7 million at the end of 2024. The 8-K does not say what the board expects the split to do for the share price or for the Nasdaq listing.
The business
Rockwell describes itself as a healthcare company that develops, manufactures, commercializes and distributes hemodialysis products for dialysis providers. The 10-K says it is a supplier of liquid and dry, acid and bicarbonate concentrates in the United States. Hemodialysis is the most common form of end-stage kidney disease treatment, usually given at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities or in a patient's home. Rockwell says that is a large market opportunity and that it believes its products are well positioned to meet patients' needs.
The company makes its concentrates under current Good Manufacturing Practices and delivers most of its concentrates and mixers to clinics across the United States and abroad, using its own delivery trucks and third-party carriers. Its CitraPure, Dri-Sate, RenalPure and SteriLyte names are registered trademarks.
Its concentrates are made at two facilities, in Michigan and Texas, and its dry acid concentrate mixers at a facility in Iowa. Rockwell says it concluded manufacturing at a South Carolina facility in the third quarter of 2025 to streamline operations. It was incorporated in Michigan in 1996, re-domiciled to Delaware in 2019 and is based in Wixom, Michigan.
The 8-K lists the common stock, par value $0.0001, as registered on the Nasdaq Capital Market under the symbol RMTI. Whether a split follows, and on what terms, is not set out in the filing.